S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
NYSEAMERICAN:BTX

Brooklyn ImmunoTherapeutics Stock Forecast, Price & News

$9.48
-0.56 (-5.58 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.41
$10.12
50-Day Range N/A
52-Week Range
$3.59
$80.67
Volume718,524 shs
Average Volume4.81 million shs
Market Capitalization$490.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Brooklyn ImmunoTherapeutics and its competitors with MarketBeat's FREE daily newsletter.


Brooklyn ImmunoTherapeutics logo

About Brooklyn ImmunoTherapeutics

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.24 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX) Frequently Asked Questions

What stocks does MarketBeat like better than Brooklyn ImmunoTherapeutics?

Wall Street analysts have given Brooklyn ImmunoTherapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Brooklyn ImmunoTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Brooklyn ImmunoTherapeutics?

Brooklyn ImmunoTherapeutics saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,070,000 shares, a decline of 22.5% from the August 15th total of 1,380,000 shares. Based on an average daily trading volume, of 1,930,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately 4.4% of the company's shares are sold short.
View Brooklyn ImmunoTherapeutics' Short Interest
.

When is Brooklyn ImmunoTherapeutics' next earnings date?

Brooklyn ImmunoTherapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Brooklyn ImmunoTherapeutics
.

How were Brooklyn ImmunoTherapeutics' earnings last quarter?

Brooklyn ImmunoTherapeutics, Inc. (NYSEAMERICAN:BTX) released its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.06. The biotechnology company earned $1.27 million during the quarter, compared to analyst estimates of $1.75 million.
View Brooklyn ImmunoTherapeutics' earnings history
.

Who are Brooklyn ImmunoTherapeutics' key executives?

Brooklyn ImmunoTherapeutics' management team includes the following people:
  • Howard J. Federoff, President, Chief Executive Officer & Director
  • Sandra Gurrola, Vice President-Finance
  • Kevin A. D'Amour, Chief Scientific Officer
  • Jay Sial, Chief Administrative & Scientific Officer
  • Ronald Guido, Chief Development Officer

What other stocks do shareholders of Brooklyn ImmunoTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brooklyn ImmunoTherapeutics investors own include CA (CA), Asterias Biotherapeutics (AST), Geron (GERN), Micron Technology (MU), BlackRock (BLK), Endologix (ELGX), OPKO Health (OPK), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP) and Chipotle Mexican Grill (CMG).

What is Brooklyn ImmunoTherapeutics' stock symbol?

Brooklyn ImmunoTherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

Who are Brooklyn ImmunoTherapeutics' major shareholders?

Brooklyn ImmunoTherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (3.18%), Cypress Point Wealth Management LLC (1.07%), State Street Corp (0.99%), Vanguard Group Inc. (0.93%), Geode Capital Management LLC (0.81%) and Nuveen Asset Management LLC (0.62%). Company insiders that own Brooklyn ImmunoTherapeutics stock include Charles Cherington and George P Denny III.
View institutional ownership trends for Brooklyn ImmunoTherapeutics
.

Which institutional investors are selling Brooklyn ImmunoTherapeutics stock?

BTX stock was sold by a variety of institutional investors in the last quarter, including Bridgeway Capital Management LLC. Company insiders that have sold Brooklyn ImmunoTherapeutics company stock in the last year include Charles Cherington, and George P Denny III.
View insider buying and selling activity for Brooklyn ImmunoTherapeutics
or view top insider-selling stocks.

Which institutional investors are buying Brooklyn ImmunoTherapeutics stock?

BTX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Cypress Point Wealth Management LLC, State Street Corp, Vanguard Group Inc., Geode Capital Management LLC, Nuveen Asset Management LLC, Northern Trust Corp, and Susquehanna International Group LLP.
View insider buying and selling activity for Brooklyn ImmunoTherapeutics
or or view top insider-buying stocks.

How do I buy shares of Brooklyn ImmunoTherapeutics?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brooklyn ImmunoTherapeutics' stock price today?

One share of BTX stock can currently be purchased for approximately $9.48.

How much money does Brooklyn ImmunoTherapeutics make?

Brooklyn ImmunoTherapeutics has a market capitalization of $490.40 million.

How many employees does Brooklyn ImmunoTherapeutics have?

Brooklyn ImmunoTherapeutics employs 2,018 workers across the globe.

What is Brooklyn ImmunoTherapeutics' official website?

The official website for Brooklyn ImmunoTherapeutics is www.biotimeinc.com.

Where are Brooklyn ImmunoTherapeutics' headquarters?

Brooklyn ImmunoTherapeutics is headquartered at 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States.

How can I contact Brooklyn ImmunoTherapeutics?

Brooklyn ImmunoTherapeutics' mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (212) 582-1199.


This page was last updated on 9/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.